A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

NCT03416374 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed and/or Refractory Multiple Myeloma

Interventions

DRUG: Ixazomib
DRUG: Bortezomib
DRUG: Carfilzomib
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Takeda